Search
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigational[A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act.
Benzophenone
go.drugbank.com/drugs/DB01878ApprovedSubstituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreen.
Pentolinium
go.drugbank.com/drugs/DB01090ApprovedPentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
Methazolamide
go.drugbank.com/drugs/DB00703ApprovedA carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Ibandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Mixtures: ASCENDRA TRIO 500CA+1000D3Products: ACIDO IBANDRONICO DOC GENERICIFB-101
go.drugbank.com/drugs/DB17956InvestigationalDeveloped by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]
Angiotensin II
go.drugbank.com/drugs/DB11842ApprovedInvestigationalAs of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure … As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTF is a novel target for cancers, as it is often overexpressed on solid tumours, including cervical cancer, and it is associated with poor clinical outcomes. … [L38429] Tisotumab vedotin-tftv is marketed under the trade name Tivdak as an intravenous injection. On April 29, 2024, tisotumab vedotin was granted full FDA approval.
Thymol
go.drugbank.com/drugs/DB02513ApprovedInvestigationalIt is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)